help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Long, X.
Right arrow Articles by Bigsby, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Long, X.
Right arrow Articles by Bigsby, R. M.
Endocrinology Vol. 142, No. 12 5390
Copyright © 2001 by The Endocrine Society

MISCELLANEOUS

Evidence for Estrogenic Contamination of the MAPK Inhibitor PD98059

Xinghua Long, Edward A. Gize, Kenneth Nephew and Robert M. Bigsby

Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202

PD98059 blocks phosphorylation and activation of MAPK proteins, ERK1 and ERK2. In the course of examining the effect of PD98059 on estrogen-induced transcription of reporter genes in a human breast cancer cell line and in yeast, we found that two of four different batches of PD98059 produced estrogenic effects in a dose-dependent manner. In a competitive binding assay, these preparations of PD98059 displaced radiolabeled estradiol from ER{alpha}. Furthermore, in the yeast assay, addition of a coactivator protein, AIB1, enhanced the transcriptional effect of PD98059, indicating that it induces receptor-coactivator interactions. Although concentrations of PD98059 required to activate ER{alpha} in these experimental systems are 104- to 105 higher than the concentration of estradiol required to do the same, the concentrations required to block MAPK activation are well above those which would produce maximal estrogenic effects. Thus, when PD98059 is used in estrogen-responsive cells, contaminating estrogenic activity may confound interpretation of experimental results.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
X. Long, M. Fan, R. M. Bigsby, and K. P. Nephew
Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-{alpha}-dependent and estrogen receptor-{alpha}-independent mechanisms
Mol. Cancer Ther., July 1, 2008; 7(7): 2096 - 2108.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
B. Tan, X. Long, H. Nakshatri, K. P Nephew, and R. M Bigsby
Striatin-3{gamma} inhibits estrogen receptor activity by recruiting a protein phosphatase
J. Mol. Endocrinol., May 1, 2008; 40(5): 199 - 210.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
X. Zhao, H. Lorenc, H. Stephenson, Y. J. Wang, D. Witherspoon, B. Katzenellenbogen, D. Pfaff, and N. Vasudevan
Thyroid hormone can increase estrogen-mediated transcription from a consensus estrogen response element in neuroblastoma cells
PNAS, March 29, 2005; 102(13): 4890 - 4895.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2001 by The Endocrine Society